Literature DB >> 10629678

Acute asthma in the pediatric emergency department.

S R Smith1, R C Strunk.   

Abstract

The management of children with acute asthma remains a difficult and challenging process. Although newer asthma medications are being developed, they are unlikely to have a large impact on the management of children with acute asthma. The leukotriene inhibitors are new anti-inflammatory agents for asthma and are beneficial for the treatment of patients with chronic asthma but have no therapeutic effect during the acute phase of an exacerbation. Older treatments, including the use of magnesium and heliox, have been revisited. Although some children with severe asthma may respond, these do not provide relief for most children with acute exacerbation. The new challenge for asthma care is finding ways to link children with their primary care providers so that regular asthma care can be established. The NHLBI recommends that children with asthma have regular visits with their primary care providers (e.g., four times a year). Regular care results in better adherence to medical and preventive management plans and improves the relationship between patients and physicians. Instituting an asthma action plan, which instructs families on when and how to begin therapy for an acute exacerbation, may prevent progression to a more severe condition.

Entities:  

Mesh:

Year:  1999        PMID: 10629678     DOI: 10.1016/s0031-3955(05)70179-6

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  2 in total

1.  A retrospective study evaluating the effectiveness of an asthma clinical pathway in pediatric inpatient practice.

Authors:  Elisa Edwards; Kristie Fox
Journal:  J Pediatr Pharmacol Ther       Date:  2008-10

2.  Transient occult cardiotoxicity in children receiving continuous beta-agonist therapy.

Authors:  Christopher L Carroll; Melinda Coro; Allison Cowl; Kathleen A Sala; Craig M Schramm
Journal:  World J Pediatr       Date:  2014-03-06       Impact factor: 2.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.